Frustrated by the lack of manufacturing capacity for biologic medicines made from cells, viruses, or genetic materials, West Coast venture industry legend Nelsen conceived National Resilience, which launched in 2020 with $800 million in capital. Last year, the company took over the hulking Genzyme/Sanofi plant in Allston, Mass., committed $30 million to stem-cell research at Harvard, and signed a deal to produce hundreds of millions of doses of Moderna’s mRNA vaccine, Spikevax. “Sometimes you just have to act instead of talking,” Nelsen tweeted.
From STAT:
